StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a research report released on Monday. The firm issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
Shares of NYSE:BTX opened at $6.23 on Monday. The stock has a market capitalization of $366.49 million, a price-to-earnings ratio of -2.74 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a one year low of $5.10 and a one year high of $8.31. The company has a 50-day simple moving average of $4.96 and a 200-day simple moving average of $2.15.
Brooklyn ImmunoTherapeutics Announces Dividend
The company also recently announced a monthly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, March 14th were issued a $0.0862 dividend. This represents a $1.03 annualized dividend and a dividend yield of 16.59%. The ex-dividend date of this dividend was Friday, March 14th. Brooklyn ImmunoTherapeutics’s payout ratio is -38.33%.
About Brooklyn ImmunoTherapeutics
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
See Also
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- Dividend Payout Ratio Calculator
- Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore
- What Does a Stock Split Mean?
- Are Tariffs Threatening Disney’s Comeback Story?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Is Alphabet a Generational Buying Opportunity at These Levels?
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
